Marketing strategy

Valbiotis accelerates its marketing strategy – October 07, 2022

LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News:

Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a Research and Development company committed to scientific innovation to prevent and combat metabolic and cardiovascular diseases, is accelerating its commercial strategy.

Sébastien PELTIER, Chairman of the Board of Directors of Valbiotis, declares: “We are now starting a complementary development cycle to market our innovative active ingredients, with the aim of providing breakthrough solutions to reduce the risk factors of cardio-metabolic diseases. Our new strategy aims to accelerate Valbiotis’ growth and boost its capacity for innovation by relying on two main levers: on the one hand, the signing of international partnerships (global or regional) with major players in the nutrition and health, supported by the specialist firm AEC Partners1, and on the other hand, the proper marketing of its products on the French market. This dual value-creating strategy will enable Valbiotis to quickly target the global food supplement market, estimated at 250 billion euros in 2025, with annual growth of 9.6%, including 3.2 billion euros for France, with annual growth of 7.3%2. The exponential demand for non-drug natural preventative products, market research3 conducted with healthcare professionals and patients/consumers, combined with our recent positive Phase II clinical results for TOTUM•070, have led us to adapt our marketing strategy.”

Committed to the prevention and fight against metabolic and cardiovascular diseases through the development of unique combinations of molecules of plant origin since 2014, Valbiotis now has a portfolio of four active ingredients in advanced development phase with TOTUM•63 in prediabetes, TOTUM•070 in LDL (“bad cholesterol”) hypercholesterolemia, TOTUM•854 in the reduction of blood pressure and TOTUM•448 in the management of metabolic liver diseases (NAFL and NASH). This solid pipeline of four products with proven efficacy based on preclinical and clinical data is the result of eight years of sustained R&D activities. Valbiotis is now entering a new phase of its development focused on generating revenue and structuring the company to give this product portfolio every chance of success on a global scale.

Organization around three strategic axes for Valbiotis

  • Firstly, the search for international licensing or distribution agreements for TOTUM•070, TOTUM•448 and TOTUM•854 with major players in nutrition and health, in addition to the global strategic partnership already signed for TOTUM•63 in February 2020 with Nestlé Health Science. This key activity is supported by AEC Partners, the firm that has already worked on the partnership with Nestlé Health Science on behalf of Valbiotis, and by the creation of an internal business development and co-leadership team.
  • On the other hand, the direct marketing in France of TOTUM•070, TOTUM•448 and TOTUM•854 will enable Valbiotis to rapidly and independently develop its sales and maximize its medium-term profitability.
  • Thirdly, Valbiotis will continue its structuring to secure the supply chain for future commercializations, and will continue its research efforts to prepare the pipeline of tomorrow and complete the clinical processes in order to obtain proprietary health claims for the majority of them. .

The commercialization of the active ingredients of TOTUM prior to obtaining these exclusive health claims will make it possible to respond as quickly as possible to significant needs, currently insufficiently satisfied, in terms of preventing cardio-metabolic diseases. Only in the United States and Europe (TOP 54), 174 million adults are affected by moderate hypercholesterolemia, 124 million by moderate hypertension and 130 million by metabolic liver disease5. Within these target populations, the demand for both effective preventive products and plant substances is driven by strong underlying trends.

Internationally, the signing of licensing or distribution agreements
Backed by its portfolio of four TOTUM active ingredients that have demonstrated their effectiveness in these widespread pathologies, Valbiotis is confident in its ability to soon conclude licensing or distribution agreements with major players in nutrition and health, with a view to market internationally. . The consulting firm AEC Partners supports Valbiotis in this search for new major partnerships, following the one signed in February 2020 with Nestlé Health Science Worldwide for TOTUM•63, now in the final phase of clinical studies (Phase II/III). The new licensing or distribution partnerships will be global (outside France) or regional. Valbiotis’ ambition is to finalize the signing of international licensing or distribution agreements for TOTUM•070 by the second half of 2023.

In France, the deployment of a direct marketing model
In France, apart from TOTUM•63 which benefits from a 100% global partnership with Nestlé Health Science, the three other active ingredients will be marketed directly by Valbiotis. The marketing strategy will rely on internal medical promotion agents (APM) who will focus on key prescribers such as general practitioners, certain specialists and pharmacists. The latter will recommend the active ingredients of TOTUM according to the cardiometabolic profile of their patients. At the same time, consumers/patients will be directly targeted via an appropriate digital marketing strategy. The distribution channels envisaged will be pharmacies, drugstores and online sales.

TOTUM•070, whose Phase II clinical study was crowned with success, will be the first product marketed by Valbiotis in France. Its launch is scheduled for the first half of 2024, followed by TOTUM•448 and TOTUM•854 in 2024-2025.

Continuation of structuring and research efforts
The third strategic priority is to continue structuring the business with the aim of optimizing the supply value chain of TOTUM•63, as foreseen in the contract with Nestlé Health Science, but also to develop capacities for other portfolio products.

At the same time, innovation efforts will continue. Valbiotis’ proprietary R&D platform, specifically designed for plant research, will remain at the heart of the company’s DNA, in order to fuel the pipeline for years to come, including the exploration of microalgae produced in New Caledonia, through an exclusive agreement with ADECAL-Technopole and IFREMER (press release of September 24, 2021).

Execution of the strategy will be funded by Valbiotis cash and expected revenues from the partnership with Nestlé Health Science (which has already generated €8 million in cash since signing). It is also conditional on obtaining additional financing, the terms of which are currently being studied.

About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation to prevent and combat metabolic and cardiovascular diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach, aiming to revolutionize health by developing a new class of health nutrition products intended to reduce the risk of major metabolic diseases, based on a multi-target strategy enabled by the use of plant resources. land and sea.

Its products are intended to be licensed to players in the health sector.

Created in early 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has set up three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec (Canada).

Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has also obtained the status of “Young Innovative Company” and has received significant financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a company eligible for PEA-PME.

For more information on Valbiotis, visit: www.valbiotis.com

Name: Valbiotis
ISIN Code: FR0013254851
Stock symbol: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational assumptions and on the information available to Valbiotis to date. However, this does not in any way constitute a guarantee of future performance, and these projections may be affected by changes in economic and financial market conditions, as well as by certain risks and uncertainties, in particular those described in the Universal Registration Document. of Valbiotis filed with the Autorité des Marchés Financiers (AMF) on May 19, 2022. This document is available on the Company’s website (www.valbiotis.com). This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation to buy or subscribe to shares or financial securities of Valbiotis in any country whatsoever.

_____________________________

1 AEC Partners: a life sciences company specializing in market access, licensing and strategy consulting.

2 Panorama of the food supplements market 2020-2021, Nutrikeo.

3 Medical-marketing studies conducted in 2022 by IFOP and A+A at the request of Valbiotis, in France, Germany and the United States.

4 France, Germany, Italy, Spain, United Kingdom

5 Preliminary LDL, pre-HTA and NAFL market estimate, AEC Partners, 2020

See the source version on businesswire.com: https://www.businesswire.com/news/home/20221006005955/en/

Corporate communication / Valbiotis
Carole ROCHER
Communication and Public Affairs Director

Media relations / PrPa
Damien MAILLARD
Operational manager
+33 6 80 28 47 70
[email protected]

Financial communication / Actifin
Stéphane RUIZ
Associate Director
+33 1 56 88 11 14
[email protected]